Mechanisms of endocrine resistance in breast cancer-中华乳腺病杂志（电子版）

文章信息/Info

作者:: Per;E;Lφnning; Section of Oncology, Institute of Medicine, University of Bergen, and Department of Oncology, Haukeland University Hospital, N-5021, Bergen, Norway

摘要:: The term “therapy resistance冶, in many ways, is not a uniform term. First, it is important to distinguish therapy failure from prognostication[1] . While, on the one hand, the fact that a tumor recurrence means that some tumor cells must have survived despite the therapy applied, the fact that example lymph node negative tumors have a lower risk of relapse as compared with node positive ones relate to tumor biology, or metastatic propensity, a factor independent of those biological parameters that may cause drug resistance. Second, there are several definitions of drug resistance. Considering pre-surgical therapy or treatment for metastatic disease, therapy failure, in general, would mean lack of tumor shrinkage in response to treatment. As for adjuvant therapy, any tumor relapsing subsequent to treatment should be considered a failure. Finally, therapy failures are grouped into primary failures (or primary drug resistance) and secondary failures(secondary drug resistance), the latter occurring subsequent to an initial response.